SAN DIEGO, Oct. 25 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. announced today the initial public offering of 6,000,000 shares of common stock at a price of $9 per share. All shares are being offered by Cadence Pharmaceuticals. Cadence Pharmaceuticals’ common stock will be listed on the NASDAQ Global Market under the trading symbol “CADX.”
Merrill Lynch & Co. acted as sole book-running manager and Deutsche Bank Securities Inc. acted as co-lead manager for the offering. In addition, Pacific Growth Equities, LLC and JMP Securities LLC acted as co-managers for the offering. Cadence Pharmaceuticals has granted the underwriters a 30-day option to purchase up to an additional 900,000 shares to cover over-allotments, if any.
Any offer or sale will be made only by means of a written prospectus forming part of the effective registration statement. Copies of the final prospectus relating to the offering may be obtained from: Merrill Lynch & Co., 4 World Financial Center, New York, New York 10080 (telephone: 866-500-5408).
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 24, 2006. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. Cadence currently has two Phase III products in development, including one for the treatment of acute pain and one for the prevention of catheter-related infections.
Contacts: William R. LaRue Susan Neath SVP & Chief Financial Officer Media & Investor Relations Cadence Pharmaceuticals, Inc. Porter Novelli Life Sciences 858-436-1400 619-849-6007
Source: Cadence Pharmaceuticals, Inc.
